Study Title
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)
Purpose
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
For more information please visit
https://clinicaltrials.gov/study/NCT06120491
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
** WK New Format
IRB Number:
Trial Type:
Device
Sponsor:
** WK New Format
Contact Information: